格隆汇12月8日丨瑞华泰(688323.SH)公布，公司于2025年12月8日收到航科新世纪科技发展（深圳）有 限公司出具的《关于股份变动触及1%刻度的告知函》，2025年11月26日至2025年12月8日期间，航科新 世纪科技发展（深圳）有限公司通过集中竞价的方式减持公司股份100万股，所持有公司股份数量由 4208.31万股减少至4108.31万股，占公司当前总股本的比例由23.38%减少至22.82%，触及1%的整数倍。 ...

瑞华泰公告称，2025年11月26日至12月8日，航科新世纪科技发展（深圳）有限公司通过集中竞价减持 公司股份100万股，持股数由4208.3059万股降至4108.3059万股，占公司总股本比例由23.38%降至 22.82%，触及1%整数倍。本次减持是股东履行减持计划，不触及要约收购，不影响公司无实控人状 态、第一大股东地位、治理结构和持续经营，且未违反承诺。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002585 | 双星新材 | 7.62 | 9.96% | 20.73万 | 1.58亿 | | 301003 | 江苏博云 | 39.34 | 6.41% | 3.00万 | · 1.17 乙 | | 002838 | 道恩股份 | 24.41 | 6.08% | 9.60万 | 2.32亿 1 | | 688669 | 緊石化学 | 22.00 | 5.26% | 3.09万 | 6718.82万 | | 601208 | 东材科技 | 20.76 | 5.22% | 75.56万 | 15.57 乙 | | 600135 | 乐凯胶片 | 8.64 | 4.98% | 44.07万 | 3.81亿 | | 688323 | 瑞华泰 | 18.35 | 4.80% | 18.53万 | 3.35 Z | | 002632 | 道明光学 | 15.67 | 4.47% | 143.97万 | 21.91亿 | | 301019 | 宁波色母 | ...

Core Viewpoint - Haichuang Pharmaceutical's self-developed drug, Deuteroenzalutamide soft capsule, has been included in the national medical insurance drug list, effective from January 1, 2026, marking a significant milestone for the company and the treatment of metastatic castration-resistant prostate cancer (mCRPC) [1][2] Group 1 - Deuteroenzalutamide soft capsule is a first-class new drug developed by Haichuang Pharmaceutical, specifically for treating mCRPC, and is recognized as a second-generation androgen receptor inhibitor [1] - The drug is the first domestically approved innovative medication for adult patients with mCRPC who have progressed after treatment with abiraterone acetate and chemotherapy, and have not previously received new androgen receptor inhibitors [1] - The drug demonstrates superior safety compared to other new endocrine therapies, significantly reducing the incidence of central nervous system adverse events and avoiding rash-related side effects, while also lowering the risk of common complications in elderly patients [1] Group 2 - The inclusion of Deuteroenzalutamide soft capsule in the national medical insurance drug list reflects the recognition of its clinical value, patient benefits, and innovation by the National Healthcare Security Administration [2] - This inclusion is expected to facilitate market promotion of the drug, reduce the financial burden on patients, and enhance drug accessibility [2] - Haichuang Pharmaceutical plans to actively support the implementation of medical insurance policies and continue to promote hospital access and core market coverage to meet patient medication needs more broadly [2]

资金流向方面，该股今日全天主力资金净流入2212.47万元。（数据宝） 瑞华泰12月5日龙虎榜 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 1868.42 | | 摩根大通证券(中国)有限公司上海银城中路证券营业部 | 1701.15 | | 东莞证券股份有限公司东莞长安分公司 | 1148.66 | | 中信证券股份有限公司上海分公司 | 1085.44 | | 瑞银证券有限责任公司上海花园石桥路证券营业部 | 1049.37 | | 卖出营业部名称 | 卖出金额(万元) | | 世纪证券有限责任公司江西分公司 | 1770.82 | | 机构专用 | 923.65 | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 811.10 | | 财达证券股份有限公司邯郸人民西路证券营业部 | 686.99 | | 摩根大通证券(中国)有限公司上海银城中路证券营业部 | 670.66 | 12月5日瑞华泰（688323）收盘价17.51元，收盘上涨16.58%，全天换手率7.83%，振幅17.91% ...

证券日报网讯12月4日，瑞华泰在互动平台回答投资者提问时表示，在新能源电池领域，公司目前在复 合集流体、负极PI粘结剂等方面，积极配合下游客户的研发及试用诉求。后续进展情况，公司将按照相 关法律法规规定，及时履行信息披露义务。 ...

Core Viewpoint - Ruhi Tai is positioned at the upstream of the electronic industry chain, with products widely used in flexible circuit boards and flexible electronic substrates, ultimately applicable to various smart terminals, including AR glasses as a consumer electronics application scenario [1] Group 1 - The company operates in the upstream segment of the electronic industry chain [1] - Products are extensively utilized in flexible circuit boards and flexible electronic substrates [1] - The end applications of these products include various smart terminals, highlighting AR glasses as a specific consumer electronics application [1]

（记者 王晓波） 瑞华泰（688323.SH）12月4日在投资者互动平台表示，公司处于电子产业链最上游，产品广泛应用于 柔性线路板及柔性电子基材，最终可应用于各类智慧终端，AR眼镜是消费电子终端的应用场景之一。 每经AI快讯，有投资者在投资者互动平台提问：公司的产品有用于智能穿戴设备AR眼镜否？ ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688323 证券简称：瑞华泰 公告编号：2025-052 转债代码：118018 转债简称：瑞科转债 深圳瑞华泰薄膜科技股份有限公司 关于独立董事辞职暨补选独立董事并调整董事会专门委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 二、补选独立董事并调整董事会专门委员会委员情况 为完善公司治理结构，保证公司董事会的规范运作，根据有关法律法规及《公司章程》的规定，经公司 董事会提名，第三届董事会提名委员会资格审查同意，公司于2025年12月3日召开第三届董事会第七次 会议，审议通过了《关于补选第三届董事会独立董事并调整董事会专门委员会委员的议案》，同意提名 武晶茹女士为公司第三届独立董事候选人(简历详见附件1)，任期自公司2025年第三次临时股东会审议 通过之日起至第三届董事会任期届满之日止。武晶茹女士已取得上海证券交易所认可的相关培训证明材 料，其任职资格和独立性已经上海证券交易所审核无异议通过。 深圳瑞华泰薄膜科技股份有限公司(以下简称"公司")董事 ...

Core Viewpoint - Shenzhen Rayitek Film Technology Co., Ltd. is convening its third extraordinary general meeting of shareholders in 2025 on December 19, 2025, to discuss various matters including the election of a new independent director following the resignation of an existing director [18][19]. Meeting Details - The meeting will take place on December 19, 2025, at 14:30, with both on-site and online voting options available through the Shanghai Stock Exchange's voting system [2][4]. - Shareholders can vote online from 9:15 to 15:00 on the same day, with specific time slots for trading system voting [2][4]. Voting Procedures - The voting process will include both on-site and online methods, and shareholders must complete voting for all proposals before submission [6][8]. - Shareholders holding multiple accounts can aggregate their voting rights across all accounts, but repeated votes will be counted based on the first submission [7]. Attendance and Registration - Shareholders registered by the close of trading on the day before the meeting are entitled to attend, and they may appoint proxies to represent them [9][11]. - Registration for attendance will occur on December 16, 2025, with specific documentation required for both individual and corporate shareholders [11][12]. Director Resignation and Replacement - Independent director Huang Hua has resigned due to work commitments, and his resignation will take effect after a new independent director is elected [19][20]. - Wu Jingru has been nominated as the candidate for the independent director position, pending approval at the upcoming shareholder meeting [19][21]. Committee Adjustments - If elected, Wu Jingru will also serve on various board committees, including the audit committee, ensuring the board's operational integrity [21].